Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Bull Exp Biol Med ; 176(5): 567-571, 2024 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-38724809

RESUMEN

The expression of marker proteins of acute kidney injury after administration of high doses of lithium carbonate was assessed to evaluate the possibility of lithium use in neutron capture therapy. In mice with implanted skin melanoma B16, the expression of Kim1 (kidney injury molecule 1) and NGAL (neutrophil gelatinase-associated lipocalin) proteins in the kidneys was evaluated immunohistochemically 15, 30, 90, 180 min, and 7 days after peroral administration of lithium carbonate at single doses of 300 and 400 mg/kg. An increase in the expression of the studied proteins was found in 30 and 90 min after administration of 400 mg/kg lithium carbonate, however, 7 days after the drug administration, the expression returned to the level observed in the control group. It can be suggested that single administration of lithium carbonate in the studied doses effective for lithium neutron capture therapy will not significantly affect the renal function.


Asunto(s)
Lesión Renal Aguda , Receptor Celular 1 del Virus de la Hepatitis A , Lipocalina 2 , Carbonato de Litio , Animales , Lipocalina 2/metabolismo , Ratones , Lesión Renal Aguda/metabolismo , Lesión Renal Aguda/inducido químicamente , Carbonato de Litio/administración & dosificación , Receptor Celular 1 del Virus de la Hepatitis A/metabolismo , Masculino , Melanoma Experimental/metabolismo , Melanoma Experimental/tratamiento farmacológico , Melanoma Experimental/patología , Riñón/efectos de los fármacos , Riñón/metabolismo , Riñón/patología , Neoplasias Cutáneas/patología , Neoplasias Cutáneas/metabolismo , Neoplasias Cutáneas/tratamiento farmacológico , Biomarcadores/metabolismo , Biomarcadores/sangre
2.
Bull Exp Biol Med ; 172(3): 359-363, 2022 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-35001306

RESUMEN

Boron neutron capture therapy (BNCT) can become an instrument for patients with malignant neoplasms of the rectum and colon. Here we evaluate the effectiveness of BNCT performed at the accelerator based epithermal neutron source at G. I. Budker Institute of Nuclear Physics, Siberian Division of Russian Academy of Sciences, in relation to subcutaneous xenografts of human colon adenocarcinoma SW-620 in SCID mice. Utilization of BNCT with boronоphenylalanine (BPA) and sodium borocaptate (BSH), which were injected intravenously into the retroorbital sinus, resulted in a significant decrease in tumor volumes compared to the control group (no radiation).


Asunto(s)
Adenocarcinoma , Terapia por Captura de Neutrón de Boro , Neoplasias Encefálicas , Neoplasias Colorrectales , Adenocarcinoma/radioterapia , Animales , Terapia por Captura de Neutrón de Boro/métodos , Neoplasias Colorrectales/radioterapia , Xenoinjertos , Humanos , Ratones , Ratones SCID , Compuestos de Sulfhidrilo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA